Literature DB >> 6253485

Characterization of the receptor for epidermal growth factor-urogastrone in human placenta membranes.

R A Hock, M D Hollenberg.   

Abstract

The binding of mouse epidermal growth factor-urogastrone (EGF-URO) to membranes from term human placenta is peptide-specific, saturable (about 20 pmol of EGF-URO bound maximally/mg of protein), reversible, and of high affinity (KD about 400 pM). Optimal binding is observed at pH 7.6. At low pH (3.5 to 5.0). EGF-URO can be reversibly dissociated from the receptor; however, exposure to pH < 3 irreversibly inactivates the receptor. The binding, which does not exhibit ligand cooperativity, exhibits an association rate constant of 6.1 x 10(-4) s-1 and a dissociation rate constant of 6.1 x 10(-4) s-1. The dissociation constant determined from the rate constants, 240 pM, is in reasonable agreement with the constant estimated by equilibrium methods. Both monovalent and divalent cations augment EGF-URO binding 2- to 3-fold. Although in general, divalent cations enhance binding at lower concentrations (optimum, 5 mM) than do monovalent cations (optimum, approximately 80 mM), there is no cation-specific effect. Neither guanine nor adenine nucleotides affect EGF-URO binding. Whereas the proteolytic enzymes (trypsin, chymotrypsin, papain, and pepsin) inactivate the receptor, neuraminidase and phospholipases A2, C, and D augment EGF-URO binding. Neuraminidase increases the number of available sites without affecting ligand affinity. Wheat germ agglutinin, concanavalin A, and phytohemagglutinin all compete for the binding of EGF-URO. The data complement previous observations of EGF-URO binding obtained in intact cells and provide a basis for the solubilization, characterization, and isolation of this receptor from a rich tissue source.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6253485

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Epidermal growth factor (urogastrone)-mediated phosphorylation of a 35-kDa substrate in human placental membranes: relationship to the beta subunit of the guanine nucleotide regulatory complex.

Authors:  K A Valentine-Braun; J K Northup; M D Hollenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

2.  Minimal hydrolysis of epidermal growth factor by gastric fluid of preterm infants.

Authors:  J R Britton; C George-Nascimento; J N Udall; O Koldovský
Journal:  Gut       Date:  1989-03       Impact factor: 23.059

3.  Decreased binding of epidermal growth factor in placentas from streptozotocin-diabetic rats.

Authors:  J F Sissom; W K Stenzel; J B Warshaw
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

4.  Localization of epidermal growth factor/transforming growth factor-alpha receptor in the human gastric mucosa. An immunohistochemical and in situ hybridization study.

Authors:  B Orsini; A Calabrò; S Milani; C Grappone; H Herbst; C Surrenti
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

5.  Differential binding and internalization of insulin-like growth factor (IGF)-I in cultured human trophoblast and JEG-3 cells: possible modulatory effect of IGF binding proteins (BP).

Authors:  B Bhaumick; E A Armstrong
Journal:  Endocrine       Date:  1995-09       Impact factor: 3.633

6.  Growth hormone enhances hepatic epidermal growth factor receptor concentration in mice.

Authors:  J O Jansson; S Ekberg; S B Hoath; W G Beamer; L A Frohman
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

7.  Epidermal growth factor receptor levels increase but epidermal growth factor receptor ligand levels decrease in mouse mammary tumors during progression from hormone dependence to hormone independence.

Authors:  C B Kienhuis; M Sluyser; C C de Goeij; P G Koenders; T J Benraad
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

8.  Somatomedin receptor of human placenta: solubilization, photolabeling, partial purification, and comparison with insulin receptor.

Authors:  B Bhaumick; R M Bala; M D Hollenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

9.  Epidermal-growth-factor-stimulated phosphorylation of calpactin II in membrane vesicles shed from cultured A-431 cells.

Authors:  J Blay; K A Valentine-Braun; J K Northup; M D Hollenberg
Journal:  Biochem J       Date:  1989-04-15       Impact factor: 3.857

10.  Evaluation of the antiinflammatory and phospholipase-inhibitory activity of calpactin II/lipocortin I.

Authors:  J K Northup; K A Valentine-Braun; L K Johnson; D L Severson; M D Hollenberg
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.